| Literature DB >> 31484384 |
Laura Moody1, Justin Shao2, Hong Chen3, Yuan-Xiang Pan4.
Abstract
Obesity and metabolic disease present a danger to long-term health outcomes. It has been hypothesized that epigenetic marks established during early life might program individuals and have either beneficial or harmful consequences later in life. In the present study, we examined whether maternal diet alters DNA methylation and whether such modifications persist after an obesogenic postnatal dietary challenge. During gestation and lactation, male Sprague-Dawley rats were exposed to either a high-fat diet (HF; n = 10) or low-fat diet (LF; n = 10). After weaning, all animals were fed a HF diet for an additional nine weeks. There were no differences observed in food intake or body weight between groups. Hepatic DNA methylation was quantified using both methylated DNA immunoprecipitation sequencing (MeDIP-seq) and methylation-sensitive restriction enzyme sequencing (MRE-seq). Overall, 1419 differentially methylated regions (DMRs) were identified. DMRs tended to be located in CpG shores and were enriched for genes involved in metabolism and cancer. Gene expression was measured for 31 genes in these pathways. Map3k5 and Igf1r were confirmed to be differentially expressed. Finally, we attempted to quantify the functional relevance of intergenic DMRs. Using chromatin contact data, we saw that conserved DMRs were topologically associated with metabolism genes, which were associated with differential expression of Adh5, Enox1, and Pik3c3. We show that although maternal dietary fat is unable to reverse offspring weight gain in response to a postnatal obesogenic diet, early life diet does program the hepatic methylome. Epigenetic alterations occur primarily in metabolic and cancer pathways and are associated with altered gene expression, but it is unclear whether they bear consequence later in life.Entities:
Keywords: DO Had; developmental programming; early life nutrition; gene-environment interactions; hepatic methylome
Mesh:
Substances:
Year: 2019 PMID: 31484384 PMCID: PMC6769607 DOI: 10.3390/nu11092075
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Methylation specific PCR (MSP) primers.
| Gene | CpG Site | Position | Methylation | Primers (5′ → 3′) | Efficiency * |
|---|---|---|---|---|---|
| Gpam | CpG 1 | Forward +52,479 | U | GTAGTGGAATAAGAAGTTTTCGGAG | 98.20% |
| Reverse +52,587 | U | ACCTTCAAATAACAATCACGCTAC | |||
| Forward +52,485 | M | AGAGTAGTAGTGGAATAAGAAGTTTTTGG | 99.10% | ||
| Reverse +52,586 | M | CACCTTCAAATAACAATCACACTAC | |||
| CpG 2 | Forward +44,337 | U | GGTGGAGAGGTATTTGTTATGGA | 108.20% | |
| Reverse +44,416 | U | CCACACAATCTACAAACTTCACAA | |||
| Forward +44,332 | M | TTAGAGGTGGAGAGGTATTTGTTAC | 101.19% | ||
| Reverse +44,414 | M | ACACAATCTACAAACTTCACGAAAA | |||
| CpG 3 | Forward +7619 | U | TGTAATTTTTTATTTTAATTTATGTGATTTTTGA | 95.56% | |
| Reverse +7736 | U | TTTCTACTTCACAATTACTAATCAACCCA | |||
| Forward +7633 | M | TTAATTTACGTGATTTTTGATTGTTATTATTTT | 98.50% | ||
| Reverse +7736 | M | CTACTTCACGATTACTAATCAACCCG | |||
| CpG 4 | Forward +7288 | U | AAGTTAAGTTGTAGTGGTTGGGTAATTG | 93.47% | |
| Reverse +7360 | U | CCCACTTATTTTAAACAACATCAAACC | |||
| Forward +7289 | M | AGTCGTAGTGGTCGGGTAATCG | 107.81% | ||
| Reverse +7357 | M | CCGCTTATTTTAAACAACATCGAA | |||
| Myh7b | CpG 1 | Forward +9089 | U | TGGGTTCGTGTGGGAAATG | 99.33% |
| Reverse +9181 | U | CCACCTCAACTCTCCCTAAACAA | |||
| Forward +9089 | M | CGGGTTCGTGTGGGAAAC | 92.99% | ||
| Reverse +9181 | M | CCGCCTCAACTCTCCCTAAA | |||
| CpG 2 | Forward +9607 | U | AGGAGTATAAATGGGAGGGTATTGATT | 91.86% | |
| Reverse +9757 | U | CATACACAACTTCCAACACCATCC | |||
| Forward +9621 | M | CGTGTTGGAGTAGGAGGAGTATAAAC | 102.11% | ||
| Reverse +9753 | M | CGCAACTTCCGACACCATC | |||
| CpG 3 | Forward +10,000 | U | TGATTTGAGGATTATGTGTATTGGATTT | 99.04% | |
| Reverse +10,069 | U | CCAATTTCTTTTTCCATTCTCCATAC | |||
| Forward +9995 | M | CGAGGATTACGTGTATTGGATTTTAA | 103.13% | ||
| Reverse +10,065 | M | TTTCTTTTTCCATTCTCCGTACAATA | |||
| CpG 4 | Forward +11,606 | U | AGGAGTGTATGTTTTTTAAGGTTTTAGATG | 96.42% | |
| Reverse +11,701 | U | AACAAAACTACTAAAAATTAAATAACTTCCCA | |||
| Forward +11,606 | M | AGGAGTGTATGTTTTTTAAGGTTTTAGACG | 98.73% | ||
| Reverse +11,701 | M | ACGAAACTACTAAAAATTAAATAACTTCCCA | |||
| CpG 5 | Forward +12,857 | U | GATTTGGATTTGTTGTTAAGGGTTTT | 102.17% | |
| Reverse +12,924 | U | AACCAACACCCACCACTACCTAA | |||
| Forward +12,859 | M | TTCGGATTTGTCGTTAAGGGTT | 106.16% | ||
| Reverse 12,927 | M | CCAACACCCACCGCTACC | |||
| CpG 6 | Forward +13,120 | U | TTATTTGGATATGGGATAAGAGAGGG | 98.27% | |
| Reverse +13,216 | U | CACCATCTAAAATAATACTACTTTCTTTCACTTAT | |||
| Forward +13,120 | M | TTATTTGGATACGGGATAAGAGAGG | 102.64% | ||
| Reverse +13,219 | M | CGTCTAAAATAATACTACTTTCTTTCGCTT |
* The qPCR amplification efficiency is calculated based on the slope of the standard curve https://www.lifetechnologies.com/us/en/home/brands/thermo-scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/qpcr-efficiency-calculator.html. Slopes between −3.1 and −3.6 giving reaction efficiencies between 90 and 110% are typically acceptable.
Gene expression primers.
| Gene | Ensembl ID | Common Name | Position | Primers (5′ → 3′) | Efficiency * |
|---|---|---|---|---|---|
| Acacb | ENSRNOT00000078868.1 | Acetyl-CoA Carboxylase Beta | Forward +1081 | ACCCCAAACTTCCAGAGC | 105.70% |
| Reverse +1189 | TGGGCTACAATGGTGGAG | ||||
| Acox3 | ENSRNOT00000049798.3 | Acyl-CoA Oxidase 3, Pristanoyl | Forward +1553 | TGACTGGTTGGACTCAGA | 94.56% |
| Reverse +1629 | TCTGATGACTCTCTCGGA | ||||
| Actb | ENSRNOT00000042459.4 | Actin Beta | Forward +451 | GAGACCTTCAACACCCCAGC | 104.67% |
| Reverse +526 | CAGTGGTACGACCAGAGGCA | ||||
| Acvr1c | ENSRNOT00000059280.4 | Activin A Receptor Type 1C | Forward +511 | TGATTTATGATGCCACTGCC | 100.24% |
| Reverse +586 | ATTGTCCTTGCGATGGTTCT | ||||
| Adh1 | ENSRNOT00000036993.4 | Alcohol Dehydrogenase 1 | Forward +257 | ATGAAGGAGTTGGGATAG | 100.37% |
| Reverse +318 | ATCACCTGTTCTTACGCT | ||||
| Adh5 | ENSRNOT00000016891.6 | Alcohol Dehydrogenase 5 | Forward +637 | GTGTGTCTGATTGGATGTGG | 117.98% |
| Reverse +700 | TGACCTTGGCAGTGTTGA | ||||
| Adh7 | ENSRNOT00000015870.4 | Alcohol Dehydrogenase 7 | Forward +262 | GAAGCAGTTGGGATTGTGGAGA | 108.18% |
| Reverse +328 | TCACTTTGTCACCTGGTCTCACTG | ||||
| Cacng8 | ENSRNOT00000078444.1 | Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8 | Forward +297 | CTGCGTGAAGATCAACCACT | 108.34% |
| Reverse +395 | ATAGGAAAGATGCTGGAGGC | ||||
| Cpt2 | ENSRNOT00000016954.3 | Carnitine Palmitoyltransferase 2 | Forward +310 | GACACCATGAAGAGATACCT | 107.28% |
| Reverse +387 | ACACAACGCTTCTGTTCT | ||||
| Dapk3 | ENSRNOT00000027634.4 | Death Associated Protein Kinase 3 | Forward +624 | TTCGTCGCCCCTGAGATTGTAA | 103.21% |
| Reverse +685 | ATGACGCCGATGCTCCACATAT | ||||
| Dcc | ENSRNOT00000064947.3 | DCC Netrin 1 Receptor | Forward +1144 | GTGGCTGAAAATGAGGCTGGC | 100.76% |
| Reverse +1208 | ATGGCAGGCTTGGGGACAA | ||||
| Enox1 | ENSRNOT00000074868.2 | Ecto-NOX Disulfide-Thiol Exchanger 1 | Forward +167 | TTGAGAGCATCGCACAGTGT | 93.82% |
| Reverse +239 | ATGCTCCCCAAACCATCA | ||||
| Fads2 | ENSRNOT00000059280.4 | Fatty Acid Desaturase 2 | Forward +711 | CGTGTTTGTCCTTGGAGAGTGGC | 108.89% |
| Reverse +790 | CATGCTGGTGGTTGTAGGGCA | ||||
| Flnb | ENSRNOT00000066546.1 | Filamin B | Forward +353 | GCTGGAGAATGTGTCTGT | 108.69% |
| Reverse +422 | ACTGTCAATGGACACGAG | ||||
| Foxo1 | ENSRNOT00000018244.5 | Forkhead Box O1 | Forward +994 | AGGATAAGGGCGACAGCAACAG | 102.12% |
| Reverse +1056 | GGGACAGATTGTGGCGAATTG | ||||
| Fzd2 | ENSRNOT00000032944.2 | Frizzled Class Receptor 2 | Forward +818 | TTTTGCCCGTCTCTGGAT | 93.13% |
| Reverse +889 | TAGGTGGTGACCGTGAAGAA | ||||
| Gapdh | ENSRNOT00000050443.4 | Glyceraldehyde-3-Phosphate Dehydrogenase | Forward +220 | CTCTACCCACGGCAAGTTCAACG | 100.39% |
| Reverse +311 | CTCGCTCCTGGAAGATGGTGATG | ||||
| Hk3 | ENSRNOT00000031935.2 | Hexokinase 3 | Forward +973 | CCCTGGTTCCTGGTGCTCAG | 119.40% |
| Reverse +1050 | CCAGCACCAGCCTTACCAGC | ||||
| Igfr1 | ENSRNOT00000019267.6 | Insulin Like Growth Factor 1 Receptor | Forward +2239 | CTGAGAGGAGGCGGAGAGATG | 109.39% |
| Reverse +2304 | TGTTCCTGCTTCGGCTGG | ||||
| Il1r1 | ENSRNOT00000019673.4 | Interleukin 1 Receptor Type 1 | Forward +393 | GGGTTCATTTGTCTCATTGTGC | 101.20% |
| Reverse +465 | TGACCTCATTTGGATACTCCGT | ||||
| Irs2 | ENSRNOT00000032918.6 | Insulin Receptor Substrate 2 | Forward +3373 | CTTGAAGCGGCTAAGTCT | 109.86% |
| Reverse +3435 | TGGCTGACTTGAAGGAAG | ||||
| Lpin3 | ENSRNOT00000022403.5 | Lipin 3 | Forward +578 | CCCTCATCGCAGCCTAAAGACAT | 108.38% |
| Reverse +657 | AGGTCAGCAGATGAAAGGTTGGC | ||||
| Map3k5 | ENSRNOT00000051496.6 | Mitogen-Activated Protein Kinase Kinase Kinase 5 | Forward +455 | GTTTTTACAACGCTGACATCGC | 105.77% |
| Reverse +525 | ATGATAAAACAGGGAAGGCTGC | ||||
| Mapk3 | ENSRNOT00000087625.1 | Mitogen-Activated Protein Kinase 3 | Forward +618 | CACTGGCTTTCTTACCGAGT | 111.47% |
| Reverse +696 | GGTGTAGCCCTTGGAGTTAA | ||||
| Mknk2 | ENSRNOT00000041106.5 | MAP Kinase Interacting Serine/Threonine Kinase 2 | Forward +177 | TTCAGGGCTTCCACCGTTCG | 107.33% |
| Reverse +246 | TGGGCGGGGTCTAAGGTGAA | ||||
| Msh3 | ENSRNOT00000018449.7 | MutS Homolog 3 | Forward +166 | TGTCCCCCACAGAACCAGCA | 109.37% |
| Reverse +229 | TTCCCCAGTGACCTCTTCCTGC | ||||
| Mttp | ENSRNOT00000014631.6 | Microsomal Triglyceride Transfer Protein | Forward +1042 | TAGAACCTGAGAACCTGTCCAACGC | 107.54% |
| Reverse +1113 | AAGTGCGGAGGTGCTGAATGAAG | ||||
| Ncoa4 | ENSRNOT00000066062.3 | Nuclear Receptor Coactivator 4 | Forward +611 | CCTAGTTCTTCAAGTGTCAGGC | 108.75% |
| Reverse +686 | TGGATGCTGACTTCTGCTCT | ||||
| Nfatc2 | ENSRNOT00000065615.1 | Nuclear Factor Of Activated T Cells 2 | Forward +1599 | GGAGCCAAAGAACAACATGCGGG | 100.47% |
| Reverse +1674 | CAGCTCGATGTCAGCGTTTCGGA | ||||
| Ntrk2 | ENSRNOT00000042145.2 | Neurotrophic Receptor Tyrosine Kinase 2 | Forward +979 | TCCTGGACAAACTCGTCA | 99.47% |
| Reverse +1058 | GGCTTACAAGGCGTTTCT | ||||
| Pik3c3 | ENSRNOT00000066816.2 | Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 | Forward +60 | CTGTGACCTGGACATCAA | 93.26% |
| Reverse +119 | TGTTCTCTCTTCCCTTCC | ||||
| Phkb | ENSRNOT00000049624.4 | Phosphorylase Kinase Regulatory Subunit Beta | Forward +369 | GCCATAAAGTGTATGAGAGGAG | 106.60% |
| Reverse +435 | TGAACTGCTGGACCTTATCA | ||||
| Ppp1r3b | ENSRNOT00000051720.2 | Protein Phosphatase 1 Regulatory Subunit 3B | Forward +838 | TATGAAAGAATGGAGTTCGCCGTG | 107.84% |
| Reverse +909 | TTTGCCTTTGTTGCTGTCCCAGTA | ||||
| Rasgrp2 | ENSRNOT00000028646.6 | RAS Guanyl Releasing Protein 2 | Forward +490 | CAAGAAGGAAACCGCAGGCAC | 108.06% |
| Reverse +565 | TCACCTGCCGCTTCCACTTGT | ||||
| Rpl7a | ENSRNOT00000044551.4 | Ribosomal Protein L7a | Forward +64 | GAGGCCAAAAAGGTGGTCAATCC | 105.33% |
| Reverse +127 | CCTGCCCAATGCCGAAGTTCT | ||||
| Runx1t1 | ENSRNOT00000066191.1 | RUNX1 Translocation Partner 1 | Forward +796 | TCCCACTGAGACCTTTTG | 109.60% |
| Reverse +894 | CAGGGTTCTGTTTGGCTA | ||||
| Scd | ENSRNOT00000018447.5 | Stearoyl-CoA Desaturase | Forward +942 | TCAATCTCGGGAGAACATCCTG | 109.77% |
| Reverse +1013 | AAGGCGTGATGGTAGTTGTGGA | ||||
| Scp2 | ENSRNOT00000015420.5 | Sterol Carrier Protein 2 | Forward +203 | GGCTATGTGTACGGTGAATCCA | 105.56% |
| Reverse +280 | AATGATAGGGATGCCAGTCAGC | ||||
| Skp2 | ENSRNOT00000089178.1 | S-Phase Kinase Associated Protein 2 | Forward +809 | CTGGATTTTCTGAGTCTGCC | 100.52% |
| Reverse +882 | CCAGGAGAGGTTCAGTTCAT | ||||
| Taok3 | ENSRNOT00000089043.1 | TAO Kinase 3 | Forward +403 | GCTGAAGCACCCGAACACCAT | 103.35% |
| Reverse +476 | ACTCCATCACCAACCAAGCGG | ||||
| Tgfb2 | ENSRNOT00000003313.5 | Transforming Growth Factor Beta 2 | Forward +1664 | ACAATGCTAACTTCTGTGCTGG | 91.24% |
| Reverse +1735 | TGAGGACTTTGGTGTGTTGTGT | ||||
| Traf3 | ENSRNOT00000010906.6 | TNF Receptor Associated Factor 3 | Forward +870 | CTCTTCTGAGGAGTGAGTTGA | 108.60% |
| Reverse +942 | CGCTTAAAACTACAGGTGC | ||||
| Wnt6 | ENSRNOT00000023439.6 | Wnt Family Member 6 | Forward +452 | GGGGGTTCGAGAATGTCAGTTCC | 103.79% |
| Reverse +517 | GCCTTGCTGTGACTGGAGCAGTT | ||||
| Zbtb16 | ENSRNOT00000045356.3 | Zinc Finger and BTB Domain Containing 16 | Forward +1695 | GCATTTACTGGCTCATTCAG | 100.89% |
| Reverse +1770 | ATCTTCCTTTGAGAACTGGG |
* The qPCR amplification efficiency is calculated based on the slope of the standard curve https://www.lifetechnologies.com/us/en/home/brands/thermo-scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/qpcr-efficiency-calculator.html. Slopes between −3.1 and −3.6 giving reaction efficiencies between 90 and 110% are typically acceptable.
Figure 1Maternal diet did not impact postnatal phenotype when followed by a high-fat (HF) diet. (A) Male Sprague-Dawley rats were given either a HF or low-fat (LF) diet during gestation and lactation (seven weeks). Both groups were given a HF diet after weaning (nine weeks; n = 10/group). (B) Caloric intake after weaning did not differ between the two groups. (C) Postnatal, and (D) final, body weight did not differ between groups.
Figure 2Maternal diet altered hepatic DNA methylation. (A) MeDIP-seq and MRE-seq were performed to quantify genome-wide DNA methylation. (B) Sequencing revealed 1,419 differentially methylated regions (DMRs) between groups (false discovery rate, FDR, p-value < 0.05), including 534 (37.6%) that were more highly methylated in the HF group and 885 (62.4%) that were more highly methylated in the LF group. (C) DMR position relative to genomic features, including intergenic regions, gene bodies, promoters, and downstream regions. (D) DMR location relative to CpG islands and shores.
Figure 3Methylation Specific PCR validates MeDIP-seq and MRE-seq findings. (A) Analysis of MeDIP-seq and MRE-seq identified a significant DMR within the gene body of the Myh7b gene (FDR p-value < 0.05). (B) The DMR spanned exon 17, intron 17/18, exon 18, and part of intron 18/19. (C) MeDIP-seq and (D) MRE-seq values are given as average reads ± standard error of the mean (SEM). (E) MSP was used to measure DNA methylation at six individual CpG sites within the DMR. (F) MSP quantities were averaged over the six sites. MSP values are reported as % DNA methylation ± SEM (* p < 0.05). (G) Among regions that were not significantly differentially methylated, four CpGs were chosen in the Gpam gene body as negative controls. (H) MeDIP-seq and (I) MRE-seq values are given as average reads ± SEM. (J) MSP was used to measure DNA methylation at the four CpG sites and (K) methylation was averaged over the four sites. MSP values are reported as % DNA methylation ± SEM (* p < 0.05).
Gene ontology clustering.
| GO Number | GO Annotation | Count | Fold Enrichment | FDR |
|---|---|---|---|---|
| Annotation Cluster 1 (Enrichment Score: 6.24) | ||||
| GO:0046872 | Metal ion binding | 111 | 1.54 | 2.37 × 10−4 |
| GO:0043167 | Ion binding | 113 | 1.52 | 1.70 × 10−4 |
| GO:0043169 | Cation binding | 111 | 1.52 | 1.61 × 10−4 |
| Annotation Cluster 2 (Enrichment Score: 5.24) | ||||
| GO:0000902 | Cell morphogenesis | 26 | 3.02 | 0.0013 |
| GO:0032989 | Cellular component morphogenesis | 26 | 2.73 | 0.0045 |
| GO:0000904 | Cell morphogenesis involved in differentiation | 20 | 3.27 | 0.0046 |
| Annotation Cluster 3 (Enrichment Score: 4.57) | ||||
| GO:0005216 | Ion channel activity | 24 | 2.83 | 0.0016 |
| GO:0005261 | Cation channel activity | 20 | 3.18 | 0.0017 |
| GO:0022838 | Substrate specific channel activity | 24 | 2.75 | 0.0018 |
| GO:0015267 | Channel activity | 24 | 2.65 | 0.0028 |
| GO:0022803 | Passive transmembrane transporter activity | 24 | 2.65 | 0.0028 |
| GO:0022836 | Gated channel activity | 20 | 2.95 | 0.0033 |
| Annotation Cluster 4 (Enrichment Score: 4.18) | ||||
| GO:0048667 | Cell morphogenesis involved in neuron differentiation | 19 | 3.63 | 0.0029 |
| GO:0000904 | Cell morphogenesis involved in differentiation | 20 | 3.27 | 0.0046 |
| GO:0007409 | Axonogenesis | 17 | 3.61 | 0.0056 |
| GO:0048666 | Neuron development | 23 | 2.62 | 0.014 |
| GO:0048812 | Neuron projection morphogenesis | 17 | 3.12 | 0.021 |
| GO:0031175 | Neuron projection development | 19 | 2.75 | 0.034 |
| GO:0048858 | Cell projection morphogenesis | 17 | 2.82 | 0.045 |
| GO:0032990 | Cell part morphogenesis | 17 | 2.71 | 0.066 |
| Annotation Cluster 5 (Enrichment Score: 4.08) | ||||
| GO:0022836 | Gated channel activity | 20 | 2.95 | 0.0033 |
| GO:0005244 | Voltage-gated ion channel activity | 15 | 3.47 | 0.0062 |
| GO:0022832 | Voltage-gated channel activity | 15 | 3.47 | 0.0062 |
| Annotation Cluster 6 (Enrichment Score: 3.45) | ||||
| GO:0051960 | Regulation of nervous system development | 17 | 2.95 | 0.036 |
| GO:0060284 | Regulation of cell development | 17 | 2.87 | 0.044 |
| GO:0045664 | Regulation of neuron differentiation | 14 | 3.31 | 0.042 |
| GO:0050767 | Regulation of neurogenesis | 15 | 2.86 | 0.086 |
Figure 4Differential methylation was most enriched in metabolic and cancer-related pathways.
DMR description.
| Gene | Function | Chromosome | Location | Genomic Feature | HF MeDIP | LF MeDIP | HF MRE | LF MRE | Conservation |
|---|---|---|---|---|---|---|---|---|---|
| ACVR1C | Cancer | 3 | 40041000–40041500 | Intron 3/8 | 2.33 (0.89) | 2.58 (1.02) | 1.64 (0) | 0 | 0.0040 (0.016) |
| CACNG2 | Cancer | 7 | 116000000–116000500 | Intron 1/3 | 8.27 (3.47) | 12.26 (4.78) | 0.74 (0.42) | 0.31 (0.24) | 0.77 (0.36) |
| CACNG8 | Cancer | 1 | 64069000–64069500 | Exon 4/4 | 2.56 (1.15) | 2.00 (0.82) | 0.27 (0) | 6.07 (0) | 0.18 (0.34) |
| DAPK3 | Cancer | 7 | 10009000–10009500 | Exon 7/9 | 12.89 (6.18) | 18.09 (10.40) | 1.10 (0.68) | 0.14 (0) | 0.38 (0.45) |
| DCC | Cancer | 18 | 69043500–69044000 | Intron 1/28 | 8.56 (3.39) | 21.00 (9.64) | 3.68 (1.51) | 2.16 (1.46) | 0.0054 (0.0087) |
| FLNB | Cancer | 15 | 19052000–19052500 | Intron 1/44 | 4.89 (2.41) | 5.98 (2.59) | 2.06 (2.03) | 0.51 (0.58) | 0.014 (0.017) |
| FZD2 | Cancer | 10 | 91707500–91708000 | Promoter | 6.27 (3.41) | 1.40 (0.55) | 0.27 (0.21) | 0.95 (0.71) | 0.061 (0.094) |
| IGF1R | Cancer | 1 | 122713500–122714000 | Intron 1/20 | 4.31 (1.20) | 3.10 (1.81) | 0.71 (0) | 1.39 (0.99) | 0.0057 (0.011) |
| IL1R1 | Cancer | 9 | 39589500–39590000 | Intron 1/10 | 7.39 (4.28) | 4.33 (1.62) | 0.12 (0) | 1.00 (0.93) | 0.0053 (0.0099) |
| MAP3K5 | Cancer | 1 | 15307000–15307500 | Intron 8/12 | 1.88 (0.83) | 4.86 (2.15) | 7.37 (0) | 1.13 (0) | 0.018 (0.050) |
| MSH3 | Cancer | 2 | 22480500–22481000 | Intron 20/23 | 10.93 (4.44) | 4.08 (2.34) | 0.42 (0.42) | 1.60 (0.93) | 0.0050 (0.014) |
| NCOA4 | Cancer | 16 | 7641000–7641500 | Promoter | 12.59 (3.16) | 5.25 (2.38) | 0.27 (0.085) | 1.10 (0.84) | 0.0026 (0.0036) |
| NFATC2 | Cancer | 3 | 159682000–159682500 | Intron 8/9 | 10.58 (5.74) | 3.06 (1.24) | 1.07 (0) | 1.73 (2.32) | 0.015 (0.0038) |
| NTRK2 | Cancer | 17 | 11700500–11701500 | Intron 12/13 | 7.81 (3.75) | 17.72 (8.57) | 4.31 (3.07) | 1.21 (1.92) | 0.28 (0.41) |
| RASGRP2 | Cancer | 1 | 209198000–209198500 | Intron 15/16 | 4.29 (2.91) | 6.10 (4.07) | 0.85 (0.14) | 0.19 (0) | 0.22 (0.33) |
| RUNX1T1 | Cancer | 5 | 28230500–28231000 | Exon 1/11 | 2.63 (1.09) | 1.00 (0) | 1.70 (1.81) | 8.70 (11.88) | 0.31 (0.43) |
| SKP2 | Cancer | 2 | 58774500–58775000 | Exon 8/10 | 8.21 (4.43) | 17.98 (10.69) | 0.93 (1.08) | 0 | 0.13 (0.30) |
| TAOK3 | Cancer | 12 | 40571000–40571500 | Intron 5/19 | 12.23 (7.54) | 7.64 (3.88) | 1.51 (2.00) | 4.16 (5.87) | 0.23 (0.41) |
| TGFB2 | Cancer | 13 | 102723000–102723500 | Intron 6/7 | 10.45 (6.36) | 4.61 (2.68) | 0.24 (0) | 3.47 (0.13) | 0.39 (0.47) |
| TRAF3 | Cancer | 6 | 135924000–135924500 | Promoter | 5.27 (2.45) | 1.50 (0.71) | 0.47 (0.57) | 10.45 (21.93) | 0.036 (0.073) |
| WNT6 | Cancer | 9 | 74115500–74117500 | Intron 3/3 | 8.30 (6.35) | 15.22 (7.88) | 3.40 (4.52) | 3.54 (5.89) | 0.26 (0.43) |
| ZBTB16 | Cancer | 8 | 52035000–52036000 | Intron 2/6 | 5.24 (2.69) | 7.58 (2.93) | 4.00 (0.63) | 0.70 (0.30) | 0.45 (0.49) |
| FOXO1 | Cancer/Metabolism | 2 | 141195500–141196000 | Intron 1/2 | 4.84 (2.03) | 1.33 (0.58) | 0.18 (0.084) | 1.31 (0.27) | 0.013 (0.026) |
| MAPK3 | Cancer/Metabolism | 1 | 185936000–185936500 | Exon 2/10 | 7.00 (3.22) | 13.88 (6.77) | 8.62 (0) | 2.72 (0) | 0.74 (0.39) |
| MKNK2 | Cancer/Metabolism | 7 | 10559000–10559500 | Exon 14/14 | 8.85 (3.70) | 14.22 (6.72) | 3.20 (2.54) | 0.98 (0.97) | 0.32 (0.42) |
| ACACB | Metabolism | 12 | 43424500–43425000 | Intron 30/58 | 4.67 (2.22) | 5.63 (2.80) | 9.21 (0.59) | 3.01 (1.59) | 0.0020 (0.0041) |
| ACOX3 | Metabolism | 14 | 80781000–80781500 | Intron 13/19 | 15.48 (9.69) | 3.00 (1.58) | 0 | 0 | 0.0047 (0.016) |
| FADS2 | Metabolism | 1 | 212532500–212533000 | Intron 4/10 | 7.83 (3.78) | 12.44 (4.55) | 1.67 (1.44) | 0.87 (0.92) | 0.27 (0.44) |
| IRS2 | Metabolism | 16 | 83384000–83384500 | Intron 1/1 | 9.39 (4.22) | 1.67 (0.71) | 0.24 (0.17) | 2.82 (0.27) | 0.00077 (0.0032) |
| PHKB | Metabolism | 19 | 22453500–22454000 | Intron 13/29 | 4.43 (2.08) | 11.92 (5.76) | 0.91 (0.18) | 0.19 (0) | 0.038 (0.12) |
| PPP1R3B | Metabolism | 16 | 60562000–60562500 | Intron 1/1 | 4.08 (2.56) | 1.00 (0) | 0.49 (0) | 6.85 (0) | 0.026 (0.076) |
| SCD1 | Metabolism | 1 | 249463500–249464000 | Intron 5/5 | 10.82 (4.11) | 16.68 (5.85) | 1.89 (1.58) | 0.47 (0.40) | 0.012 (0.037) |
MeDIP and MRE values are given as average reads (standard deviation). Conservation denotes conservation score (standard deviation).
Figure 5Gene expression in cancer and metabolism genes. Gene expression values are normalized to the geometric mean of Actb, Gapdh, and Rpl7a. * p < 0.05.
Figure 6Intergenic DMRs in conserved genomic regions were associated with metabolic genes through chromatin contacts. (A) The conservation score was calculated for every intergenic DMR and only those with scores >0.5 were considered for further analysis (n = 42). (B) Regions from the Rn4 genome build were aligned with the Hg38 genome and queried for chromatin contacts. As an example, contact maps are shown for the three DMRs with the highest conservation scores. Genes located within the DMR-associated topologically associated domain (TAD; gray bars) were used for functional analysis. (C) KEGG Pathway analysis and (D) functional clustering showed enrichment for metabolic processes.
Figure 7Expression of metabolic genes associated with intergenic DMRs. (A) Three genes were differentially expressed, including Pik3c3, Enox1, and Adh5. DMRs within 1 mb upstream and downstream of the gene body are reported for (B) Pik3c3, (C) Enox1, and (D) Adh5. MeDIP-seq and MRE-seq values are presented as average reads ± SEM.